U.S. Patent 5,439,686: Claim Scope, Expiration, Litigation Risk, and Drug-Delivery Patent Landscape

U.S. Patent No. 5,439,686 covers aqueous suspensions of sub-10-micron polymeric shells containing substantially water-insoluble agents. The core technical limitation is a biocompatible shell substantially crosslinked through disulfide bonds. The patent also claims albumin shells, sonication-based crosslinking, broad drug and excipient classes, and methods for administering the composition to a subject.[1]

The patent issued August 8, 1995. Because it predates the June 8, 1995 transition to the modern 20-year patent term, its ordinary term was generally 17 years from issuance under the applicable transition rule. The patent therefore expired in 2012, absent an unusual term extension.[2] It is not a current blocking patent for generic or innovator products.

What does U.S. Patent 5,439,686 protect?

The patent protects a drug-delivery composition having five essential elements:

Required element	Scope
Active material	A substantially water-insoluble pharmacologically active, diagnostic, or nutritional agent
Physical structure	The agent is substantially completely contained inside a polymeric shell
Particle size	The shell's largest cross-sectional dimension is no greater than about 10 microns
Shell chemistry	A biocompatible polymer substantially crosslinked through disulfide bonds
Vehicle	The shell-containing particles are suspended in a biocompatible aqueous liquid

Independent claim 1 is the principal composition claim. Independent claim 17 covers administering a claim 1 composition to a subject for delivery of a substantially water-insoluble pharmaceutical agent.[1]

The claim is platform-oriented rather than limited to one drug. It reaches compositions containing drug substances, diagnostic materials, and nutritional agents if the structural and chemical limitations are met.

How should claim 1 be construed?

Claim 1 is a combination claim. A competing product must satisfy every material limitation to fall within its literal scope.

Substantially water-insoluble agent

The patent does not limit the active to a single solubility threshold. The phrase is functional and context-dependent. The specification's listed examples indicate the intended field: paclitaxel, docetaxel, camptothecin, NSAIDs, steroids, anthracyclines, anesthetics, benzodiazepines, and barbiturates.[1]

The claim is broad enough to cover an agent that is poorly soluble in aqueous biological media but is dissolved or suspended in an oil, organic solvent, polymer-compatible liquid, or other biocompatible dispersing agent.

Substantially completely contained

The drug must be inside the polymeric shell rather than merely adsorbed on the particle surface, dispersed throughout an external matrix, or attached only to the outer surface. The phrase creates a potential factual dispute over:

drug located in the shell wall;
drug dissolved in the shell interior;
surface-associated drug;
drug leakage into the aqueous suspension;
particles having incomplete or defective shells.

A product with a porous polymer matrix may present a claim-construction issue if it lacks a discrete shell that encloses the agent.

No greater than about 10 microns

The size limitation is central. It excludes conventional large microspheres and focuses the claims on microparticles and nanoparticles. The patent does not specify a single measurement protocol in the claims. Relevant measurements could include hydrodynamic diameter, microscopy-based diameter, volume-weighted diameter, or the largest dimension of an individual particle.

The phrase “about 10 microns” creates an evidentiary margin around the numerical limit. A product with an average diameter below 10 microns may still present risk if a meaningful portion of particles exceeds the limit, particularly where the claim refers to the shell's largest cross-sectional dimension rather than average particle size.

Disulfide crosslinking

The shell must be substantially crosslinked by disulfide bonds. This distinguishes the claimed system from particles crosslinked exclusively by:

glutaraldehyde;
carbodiimide chemistry;
ionic interactions;
hydrophobic association;
ester or amide bonds;
physical entrapment without covalent crosslinking.

The claims do not require all crosslinks to be disulfide bonds. “Substantially crosslinked” leaves room for mixed chemistries, provided disulfide bonds are a material part of the crosslinked shell.

Which dependent claims materially narrow the patent?

Claims 2 through 16 add chemical, formulation, and manufacturing limitations.

Claim group	Added limitation	Commercial significance
Claims 2-5	Drug, diagnostic, and nutritional-agent categories	Expands the platform beyond pharmaceuticals
Claims 6-9	Agent dissolved or suspended in a biocompatible dispersing agent	Covers oil, hydrocarbon, alcohol, ester, ether, ketone, and glycol systems
Claim 10	Agent is not diluted	Targets concentrated payload systems
Claims 11-13	Natural or synthetic polymers bearing sulfhydryl or disulfide functionality	Defines the polymer chemistry
Claim 14	Disulfide bonds formed by sonication	Narrows the manufacturing process
Claim 15	Crosslinked protein is albumin	Most commercially recognizable species-specific limitation
Claim 16	Aqueous vehicle is water, saline, buffered media, or nutrient solution	Defines the suspension phase
Claim 17	Administration to a subject	Method-of-use protection

Claim 15 is narrower than claim 1 but potentially easier to analyze technically because it identifies albumin as the shell polymer. A product using albumin without disulfide crosslinking would not automatically satisfy claim 15.

What formulations are protected by U.S. Patent 5,439,686?

The patent reaches several formulation categories:

A poorly water-soluble drug dissolved inside a disulfide-crosslinked polymeric shell.
A poorly water-soluble drug suspended inside the shell.
A neat or undiluted drug payload inside the shell.
A drug dissolved in an oil such as soybean, coconut, olive, safflower, or cottonseed oil.
A drug dispersed in a biocompatible hydrocarbon, alcohol, ester, ether, ketone, halide, or polyalkylene glycol.
Albumin-based shells.
Suspensions in water, saline, buffered saline, amino-acid solutions, sugar solutions, vitamin solutions, or carbohydrate solutions.

The claims do not expressly require a particular route of administration, release profile, dose, concentration, injection site, or therapeutic indication. Claim 17 requires administration but does not specify intravenous, intramuscular, subcutaneous, oral, intraperitoneal, or another route.

Does the patent cover paclitaxel or Abraxane?

The patent expressly lists taxol and taxotere as examples, but the listing does not create a drug-specific monopoly independent of the structural requirements. A paclitaxel product would need to contain paclitaxel in a sub-10-micron shell that is substantially crosslinked through disulfide bonds and suspended in a biocompatible aqueous liquid.

Abraxane is an albumin-bound paclitaxel product. Its inclusion of albumin and paclitaxel does not alone establish infringement. The relevant comparison is whether the commercial particle structure has:

a polymeric shell;
substantially complete encapsulation;
disulfide-bond crosslinking;
a shell dimension within the claimed range; and
an aqueous suspension.

Abraxane's formulation and manufacturing disclosures are generally characterized as albumin-bound nanoparticle technology rather than the specific disulfide-crosslinked shell architecture claimed in U.S. Patent 5,439,686. The patent therefore would not be presumed to read on Abraxane merely because claim 3 names taxol.[3]

When did U.S. Patent 5,439,686 lose exclusivity?

The patent's ordinary term ended in 2012.

Event	Date or result
Patent issued	August 8, 1995
Governing term framework	Pre-June 8, 1995 transition rule
Ordinary term	17 years from issuance, subject to applicable exceptions
Expected expiration	August 8, 2012
Current enforceability	Expired
Current Paragraph IV relevance	None as an enforceable listed patent
Current Orange Book blocking effect	None

Under 35 U.S.C. § 154(c)(1), patents subject to the transition rule receive the longer of the applicable 20-year-from-filing term or 17 years from grant, subject to statutory exceptions. The patent's issuance date makes August 8, 2012 the operative ordinary expiration date on the available record.[2]

Patent expiration removes prospective infringement liability for activities occurring after expiration. It does not eliminate liability for conduct that occurred while the patent was enforceable, nor does it erase contractual obligations, trade-secret rights, regulatory exclusivity, or later patents covering a product.

What is the Orange Book status of U.S. Patent 5,439,686?

U.S. Patent 5,439,686 is not a current Orange Book barrier.

The FDA Orange Book lists patents submitted by an approved New Drug Application holder for a specific approved drug product. A broad drug-delivery platform patent is not automatically listed merely because it mentions a drug such as paclitaxel or doxorubicin.[4]

The patent also expired before the modern commercial relevance of several nanoparticle products. Even if a sponsor had once attempted to associate the patent with an approved product, an expired patent would not create a current approval-delay mechanism under Hatch-Waxman.

Are Paragraph IV challenges relevant?

No current Paragraph IV challenge is required against this patent because it is expired.

Paragraph IV litigation is directed at Orange Book-listed patents asserted against an abbreviated new drug application. A generic sponsor generally addresses listed patents through certifications under 21 U.S.C. § 355(j)(2)(A)(vii), including a Paragraph IV certification for a patent that is invalid, unenforceable, or will not be infringed.[5]

For U.S. Patent 5,439,686:

no current 30-month stay should arise from this patent;
no current generic launch date should be delayed by it;
a product sponsor may rely on expiration rather than litigate invalidity;
later patents covering a specific formulation, manufacturing process, or therapeutic use remain separately relevant.

Which companies are challenging the patent?

There is no current commercial challenge requirement because the patent is expired. The patent's expiration also makes historic litigation less important for present launch planning unless a company is assessing past exposure, damages, or licensing obligations.

The commercially important competitive question has shifted from this patent to later patents covering:

albumin-bound nanoparticles;
polymeric nanoparticles;
nanocrystal formulations;
liposomes;
injectable emulsions;
solvent-free formulations;
controlled-release particles;
manufacturing processes for particle-size control;
drug-specific formulations.

How strong was the patent estate?

The patent was technically broad but legally vulnerable in several respects.

Strengths

Claim 1 combines a defined particle-size ceiling with a distinctive disulfide-crosslinked shell.
The claims cover multiple therapeutic, diagnostic, and nutritional payloads.
Albumin is expressly claimed.
The polymer definition includes natural polymers and a wide range of modified synthetic polymers.
The claims address both composition and administration.
The patent's structure could have created risk for a product using a genuine disulfide-crosslinked protein shell.

Weaknesses

The claims use potentially contestable terms, including “substantially water insoluble,” “substantially completely contained,” “about 10 microns,” and “substantially crosslinked.”
The composition claim requires the simultaneous presence of a shell, disulfide crosslinking, size control, aqueous suspension, and internal encapsulation.
A product using noncovalent albumin binding, a non-shell matrix, or non-disulfide crosslinking could avoid literal infringement.
The dependent claims are narrower and could be avoided by changing the polymer, payload vehicle, or crosslinking method.
The broad genus of polymers and payloads could have faced written-description, enablement, or obviousness attacks under the standards applicable at the time.[6]

The patent was stronger as a platform disclosure than as a universal barrier to all poorly soluble-drug nanoparticle products.

How does this patent compare with later nanoparticle technologies?

Technology	Core structure	Key distinction from Patent 5,439,686
Disulfide-crosslinked albumin particles	Covalently crosslinked protein shell	Directly closest to the claimed platform
Albumin-bound nanoparticles	Drug associated with albumin particles	May lack disulfide-crosslinked shell architecture
Liposomes	Phospholipid bilayer vesicles	No polymeric disulfide shell required
Polymeric micelles	Amphiphilic polymer assemblies	Usually no fully enclosing crosslinked shell
Nanocrystals	Crystalline drug particles with stabilizers	No polymeric shell necessarily present
PLGA microspheres	Polyester matrix or particles	Crosslinking is generally not through disulfide bonds
Injectable emulsions	Drug in dispersed oil droplets	No covalent polymeric shell necessarily present

The patent's closest technical competitors are later patents directed to redox-sensitive nanocarriers, thiolated polymers, disulfide-crosslinked nanogels, and albumin nanoparticles. Expiration of U.S. Patent 5,439,686 does not eliminate those later rights.

What generic entry risks exist?

The patent creates no present generic-entry risk because it is expired. Current risks arise from later, product-specific rights.

For a poorly soluble injectable product, the relevant diligence points are:

Confirm whether the product uses a shell or a matrix.
Identify the crosslinking chemistry.
Measure particle-size distribution using the applicable regulatory and technical method.
Determine whether the active is encapsulated, adsorbed, dissolved, or suspended.
Review later formulation and manufacturing patents.
Check FDA Orange Book listings for the reference product.
Review biologic or drug-device rights where the delivery system is integrated with another regulated product.

For a generic version of a product such as an albumin-bound nanoparticle, bioequivalence and qualitative formulation requirements may be more significant than the expired patent. FDA's product-specific guidance and the reference product's approved labeling remain central to launch planning.[3][7]

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers may persist even though the patent has expired. They include:

reproducible formation of sub-10-micron particles;
control of shell thickness and drug loading;
removal of residual solvents or crosslinking reagents;
control of free drug and unencapsulated drug;
batch-to-batch particle-size distribution;
sterility and endotoxin control;
prevention of aggregation during storage;
preservation of disulfide architecture in biological media;
scale-up of sonication or other high-energy processing.

These are technical and regulatory barriers, not continuing rights under U.S. Patent 5,439,686. Later patents may protect particular process parameters, excipient combinations, particle sizes, release profiles, or methods of treating a disease.

What is the geographic coverage?

U.S. Patent 5,439,686 provides rights only in the United States. Foreign counterparts, if any, must be analyzed separately by family member, jurisdiction, prosecution history, and expiration date.

The U.S. expiration does not establish the status of corresponding patents in Europe, Japan, Canada, China, Australia, or other markets. A global launch assessment requires a family-level review of:

priority applications;
national-stage filings;
granted foreign patents;
abandonment events;
annuity payments;
supplementary protection certificates;
local term-adjustment rules;
pending continuation or divisional applications.

Key Takeaways

U.S. Patent 5,439,686 claims sub-10-micron aqueous particles with a biocompatible, disulfide-crosslinked polymeric shell.
The patent covers broad payload classes, including paclitaxel, docetaxel, diagnostic agents, and nutritional compounds.
Albumin is expressly claimed, but albumin alone is not enough to satisfy the claims.
A product must have substantially complete internal containment, a qualifying shell, disulfide crosslinking, and the claimed size and aqueous-suspension characteristics.
The patent expired in 2012 under the applicable pre-1995 patent-term framework.
It presents no current Orange Book, Paragraph IV, or generic-entry barrier.
Later patents covering albumin nanoparticles, redox-sensitive polymers, formulations, and manufacturing processes remain relevant.
The patent's historical scope was broad, but its multiple structural limitations reduced the likelihood that it covered every nanoparticle or poorly soluble-drug formulation.

FAQs

Does U.S. Patent 5,439,686 cover every albumin nanoparticle?

No. The claims require a polymeric shell substantially crosslinked through disulfide bonds, sub-10-micron dimensions, internal containment of the agent, and an aqueous suspension. Albumin nanoparticles using noncovalent binding or different crosslinking chemistry may fall outside the claims.

Is paclitaxel protected by this patent today?

No. The patent's express reference to taxol does not create current exclusivity. The patent expired in 2012. Current paclitaxel protection depends on later patents, regulatory exclusivity, formulation rights, and product-specific manufacturing patents.

Can a company launch a product covered by the expired claims?

Yes, patent expiration removes the U.S. patent barrier from future conduct. The company must still assess later patents, FDA requirements, trade secrets, contractual restrictions, and foreign rights.

Does claim 17 require intravenous administration?

No. Claim 17 requires administering the composition to a subject but does not specify an administration route. The claim could therefore encompass multiple routes if the administered composition satisfies claim 1.

Could a liposome infringe this patent?

Ordinarily, a conventional liposome would not satisfy the polymeric-shell and disulfide-crosslinking limitations. Infringement would depend on the actual composition and whether the liposome also has the claimed polymeric, crosslinked shell structure.

References

U.S. Patent No. 5,439,686, claims 1-17 (issued Aug. 8, 1995).
35 U.S.C. § 154(c)(1) (2023).
U.S. Food and Drug Administration. (2023). Abraxane (paclitaxel protein-bound particles for injectable suspension) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
21 U.S.C. § 355(j)(2)(A)(vii) (2023).
35 U.S.C. §§ 102, 103, 112 (2023).
U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0961612	⤷ Start Trial	CA 2009 00036	Denmark	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	91613	Luxembourg	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	09C0050	France	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	C00961612/01	Switzerland	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	SZ 41/2009	Austria	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	441	Finland	⤷ Start Trial
European Patent Office	0961612	⤷ Start Trial	2009C/046	Belgium	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,439,686

Summary for Patent: 5,439,686